Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Capital Employed (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Return on Capital Employed readings, the most recent being 0.01% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 24.0% year-over-year to 0.01%, compared with a TTM value of 0.01% through Dec 2025, up 24.0%, and an annual FY2025 reading of 0.01%, up 26.0% over the prior year.
  • Return on Capital Employed hit 0.01% in Q4 2025 for Apellis Pharmaceuticals, down from 0.12% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.12% in Q3 2025, with the low at 0.94% in Q4 2021.
  • Median Return on Capital Employed over the past 5 years was 0.31% (2025), compared with a mean of 0.4%.
  • The sharpest move saw Return on Capital Employed surged 73bps in 2022, then tumbled -72bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.94% in 2021, then soared by 78bps to 0.21% in 2022, then crashed by -341bps to 0.93% in 2023, then soared by 75bps to 0.23% in 2024, then skyrocketed by 103bps to 0.01% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.01%, 0.12%, and 0.31% for Q4 2025, Q3 2025, and Q2 2025 respectively.